Valuation: Cocrystal Pharma, Inc.

Market Cap 18.72M 16.74M 15.49M 14.02M 26.25M 1.78B 26.68M 186M 73.72M 932M 70.27M 68.77M 2.95B P/E 2026 *
-1.34x
P/E 2027 * -2.05x
Enterprise Value 18.72M 16.74M 15.49M 14.02M 26.25M 1.78B 26.68M 186M 73.72M 932M 70.27M 68.77M 2.95B EV / Sales 2026 *
0.17x
EV / Sales 2027 * -
Free-Float
34.29%
Yield 2026 *
-
Yield 2027 * -
1 day+2.31%
1 week+2.67%
Current month-15.49%
1 month-16.93%
3 months+7.98%
6 months-32.03%
Current year-0.73%
1 week 0.91
Extreme 0.912
1.07
1 month 0.91
Extreme 0.91
1.24
Current year 0.76
Extreme 0.76
2.03
1 year 0.76
Extreme 0.76
2.03
3 years 0.76
Extreme 0.76
3.26
5 years 0.76
Extreme 0.76
11.95
10 years 0.76
Extreme 0.76
180
Manager TitleAgeSince
Chief Executive Officer 65 03/06/2026
Chief Executive Officer 59 27/05/2021
Chief Executive Officer 66 27/05/2021
Director TitleAgeSince
Director/Board Member 89 02/01/2014
Chairman 79 27/05/2021
Director/Board Member 65 02/01/2014
Date Insider Type Main position Quantity % Market Cap. Importance
05/08/26 Buy

Director

10,000 0.0725%
03/08/26 Buy

Director

75,000 0.5440%
03/06/26 Free

Chief Executive Officer

235,000 1.7044%
Change 5-day change 1-year change 3-year change Capi.($)
+2.31%+2.67%-17.64%-42.49% 18.72M
+0.88%-0.34%+40.64%+73.05% 65.28B
-0.28%-0.23%+9.54%+77.07% 54.57B
-0.47%+1.02%+9.13%+100.70% 53.59B
-2.06%+2.90%+24.07%+48.36% 45.03B
-1.79%+0.19%+19.32%+123.62% 42.17B
-1.65%+0.96%+237.56%+823.66% 39.42B
-2.26%-4.14%+15.38%+45.53% 32.71B
-2.70%-10.77%+19.80%-6.47% 24.01B
+0.20%+14.57%+59.41%+48.53% 26.5B
Average -0.77%+2.41%+41.72%+129.15% 38.33B
Weighted average by Cap. -0.90%+2.27%+45.60%+148.31%

Financials

2026 *2027 *
Net sales 110M 98.36M 91M 82.4M 154M 10.47B 157M 1.1B 433M 5.47B 413M 404M 17.33B -
Net income -11.66M -10.42M -9.64M -8.73M -16.34M -1.11B -16.61M -116M -45.9M -580M -43.75M -42.81M -1.84B -10.75M -9.61M -8.89M -8.05M -15.07M -1.02B -15.32M -107M -42.33M -535M -40.35M -39.48M -1.69B
Net Debt - -
Projected Income Statement - Annual - Cocrystal Pharma, Inc.
Logo Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Employees
10
Date Price Change Volume
26/10/26 $0.9719 +2.31% 21,940
23/10/26 $0.9500 +4.17% 43,537
22/10/26 $0.9120 -3.35% 17,116
21/10/26 $0.9436 +0.07% 7,548
20/10/26 $0.9429 -0.39% 15,344
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cocrystal Pharma, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.9719USD
Average target price
8.000USD
Spread / Average Target
+723.13%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cocrystal Pharma, Inc.
  1. Stock Market
  2. Stocks
  3. COCP Stock